<DOC>
	<DOCNO>NCT02312232</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics levodopa , carbidopa , 3-OMD ODM-104 repeat dos 3 levodopa formulation give combination carbidopa ODM-104 .</brief_summary>
	<brief_title>Pharmacokinetic Study Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Written inform consent ( IC ) obtain . Good general health ascertain detailed medical history physical examination . Finnish speaking male 1865 year age ( inclusive ) . Normal weight define body mass index ( BMI ) &gt; 19 &lt; 32 kg/m2 ( BMI = weight/height2 ) . Weight least 60 kg . Regular intestinal transit ( recent history recurrent constipation , diarrhoea , intestinal problem ) . Participants female partner childbearing potential must adhere proper form contraception ( hormonal contraception intrauterine device female partner , additional barrier method use least one partner ) first study treatment administration 3 month endofstudy visit . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , malignancy , neurological psychiatric disease within previous 2 year . Inherited family history ( parent , sibling ) clinically significant cardiac conduction disease . Current/history inflammatory bowel disease ( IBDs ) : Colitis ulcerosa Crohn 's disease , celiac disease . Acute duodenal gastric ulcer gastritis , esophagitis , colon polyp anal fissure . Any condition require regular concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . As exception , paracetamol occasional pain allow . Intake medication could affect outcome study . Any clinically significant abnormal laboratory value physical finding ( include ECG vital sign ) opinion investigator may interfere interpretation study result constitute health risk subject take part study . Known hypersensitivity active substance excipients drug . History vasovagal collapse vagal reaction unexplained reason within 2 year tendency vasovagal reaction blood sampling . History sleep apnea . Heart rate ( HR ) &lt; 40 bpm &gt; 90 bpm 10 minute supine position screen visit predose . At screen visit : systolic blood pressure ( BP ) &lt; 90 mmHg &gt; 150 mmHg 10 minute supine position diastolic BP &lt; 50 mmHg &gt; 90 mmHg 10 minute supine position Abnormal 24hour Holter finding clinical relevance accord cardiologistÂ´s assessment screen visit . History anaphylactic/anaphylactoid reaction . History seizures exclude febrile seizure first 6 year life . Strong tendency motion sickness . Recent current ( suspect ) drug abuse . Recent current alcohol abuse ; regular drinking 21 unit per week ( 1 unit = 4 cl spirit equivalent ) . Current use nicotine containing product 5 cigarette ( equivalent ) /day and/or inability refrain use nicotine containing product study ( screen visit endofstudy visit ) . Use caffeine contain beverage 600 mg caffeine/day and/or inability refrain use caffeine contain beverage treatment period 24 hour study treatment administration . Blood donation loss significant amount blood within 90 day prior first study treatment administration . Administration another investigational drug within 90 day prior first study treatment administration . Unsuitable vein repeat venipuncture cannulation . Predictable poor compliance inability communicate well study centre personnel . Inability participate treatment period . Participation clinical drug study within 3 month prior first study treatment administration .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>